Bristol-Myers Squibb procures Nvidia Vera Rubin architecture DGX SuperPOD, uses AI to accelerate drug R&D
Bristol-Myers Squibb announces purchase of Nvidia DGX SuperPOD supercomputer based on Vera Rubin architecture, becoming the first in the life sciences industry. The new system will be used throughout drug discovery and development, can evaluate more candidate drugs simultaneously, and has helped shorten clinical trial drug preparation time by 20%-30%.
Return to original text
A short introduction is retained here; the full text from the source website is not reposted. For specific wording and subsequent updates, please refer to the original article.
Open the original article on ITHome